Clinical Performance of Paraoxonase-1-Related Variables and Novel Markers of Inflammation in Coronavirus Disease-19. A Machine Learning Approach
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: Specific clinical biomarker/severity result arises from measured COVID cohort and ML analysis with comparison groups; qualifies narrowly as retrospective clinical result. Version is non-peer-reviewed v1 and association does not establish causation.
Technology: Machine Learning
Publication: Preprint · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Original v1 Methods: retrospective 126 PCR-confirmed hospitalized COVID-19 patients, 50 healthy and 45 pre-pandemic hospital controls; measured PON1/inflammatory markers and ML variable selection/classification assess severity. Results support specific PON1-related variables and inflammatory biomarkers differentiating severity groups. Preprint, single-center, retrospective; markers are associations, not causal or prospective predictors.
- Limitation / still unknown
- Affiliation not stated in the reviewed material. Affiliation was not available in the reviewed primary bibliographic metadata.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.preprints.org/manuscript/202105.0623/v1/download
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.